HLVX vs. TWST, IMCR, VCEL, CGON, ADMA, NVAX, RXRX, KYMR, BEAM, and FUSN
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Twist Bioscience (TWST), Immunocore (IMCR), Vericel (VCEL), CG Oncology (CGON), ADMA Biologics (ADMA), Novavax (NVAX), Recursion Pharmaceuticals (RXRX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "biological products, except diagnostic" industry.
HilleVax (NASDAQ:HLVX) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
Twist Bioscience received 79 more outperform votes than HilleVax when rated by MarketBeat users. However, 100.00% of users gave HilleVax an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
HilleVax has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
86.4% of HilleVax shares are owned by institutional investors. 71.1% of HilleVax shares are owned by insiders. Comparatively, 3.9% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
HilleVax has a net margin of 0.00% compared to Twist Bioscience's net margin of -69.24%. Twist Bioscience's return on equity of -31.61% beat HilleVax's return on equity.
HilleVax has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
In the previous week, Twist Bioscience had 2 more articles in the media than HilleVax. MarketBeat recorded 5 mentions for Twist Bioscience and 3 mentions for HilleVax. Twist Bioscience's average media sentiment score of 1.21 beat HilleVax's score of 0.91 indicating that Twist Bioscience is being referred to more favorably in the news media.
HilleVax presently has a consensus target price of $29.00, indicating a potential upside of 138.88%. Twist Bioscience has a consensus target price of $42.50, indicating a potential upside of 1.43%. Given HilleVax's higher probable upside, equities analysts clearly believe HilleVax is more favorable than Twist Bioscience.
Summary
HilleVax and Twist Bioscience tied by winning 8 of the 16 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
